Description

SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002[1][2].–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Cancer-programmed cell death-Formula-C27H44N4O4-Citation–References-[1]Alice Yam, et al. Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereof. Patent. WO2021247798.|[2]De Almeida V, et al. Preclinical activity and safety of STRO-002, a novel ADC targeting folate receptor alpha for ovarian cancer. Gynecologic Oncology, 2018, 149: 50.-CASNumber-1977557-86-0-MolecularWeight-488.66-Compound Purity-99.52-SMILES-OC(/C(C)=C/[C@H](C(C)C)N(C)C([C@H](C(C)(C)C)NC([C@@H](NC)C(C)(C1=CC(N)=CC=C1)C)=O)=O)=O-Research_Area-Cancer-Solubility-DMSO : ≥ 100 mg/mL-Target-ADC Cytotoxin;Drug Metabolite;EGFR-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;JAK/STAT Signaling;Metabolic Enzyme/Protease;Protein Tyrosine Kinase/RTK-MCE Product type-ADC Related